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Introduction: Despite recent therapeutic advances, lung cancer is a 
difficult disease to manage. This study assessed clinicians’ percep-
tions of care difficulty, quality of life (QOL), and symptom reports 
for their lung cancer patients compared with their patients with 
breast, prostate, and colon cancer.
Methods: This report focused on secondary analyses from the Eastern 
Cooperative Oncology Group (ECOG) Symptom Outcomes and Practice 
Patterns (SOAPP) study (E2Z02); outcome measures included clinician 
ratings of 3106 solid tumor patients. Univariate analyses focused on pat-
terns of disease-specific perceptions; multivariable analyses examined 
whether disease-specific differences persisted after covariate inclusion.
Results: In univariate comparisons, clinicians rated lung cancer 
patients as more difficult to treat than other solid tumor patients, 
with poorer QOL and higher symptom reports. After covariates were 
adjusted, the odds of clinicians perceiving lower QOL for their lung 
cancer patients were 3.6 times larger than for patients with other 
solid tumors (odds ratio = 3.6 [95% confidence interval, 2.0–6.6]; 
p < 0.0001). In addition, the odds of clinicians perceiving weight 
difficulties for their lung cancer patients were 3.2 times larger  (odds 
ratio = 3.2 [95% confidence interval, 1.7–6.0]; p = 0.0004). No other 
outcome showed significant differences between lung versus other 
cancers in multivariable models.
Conclusion: Clinicians were more pessimistic about the well-being 
of their lung cancer patients compared with patients with other solid 
tumors. Differences remained for clinician perceptions of patient 
QOL and weight difficulty, even after controlling for such variables as 
stage, performance status, and patient-reported outcomes. These con-
tinuing disparities suggest possible perception bias. More research is 
needed to confirm this disparity and explore the underpinnings.
Key Words: Lung cancer, Nihilism, Quality of life, Care difficulty, 
Symptom reports.
(J Thorac Oncol. 2013;8: 1474–1483)
Despite recent advances in early diagnosis and treatment (e.g., computed tomography–based screening, molecular 
testing, increased efficacy of multimodal therapies), lung can-
cer remains a difficult disease to manage. Clinicians who treat 
lung cancer often encounter late-stage diagnoses, poor out-
comes, treatment toxicities, multiple comorbidities, behavioral 
risk factors, and complicated symptom burdens.1–3 On the basis 
of this complexity, clinicians might consider their individual 
lung patients to be more difficult to treat, have poorer quality of 
life (QOL), and have more troubling symptoms compared with 
their patients with other solid tumors. However, little empiri-
cal work has actually compared clinician assessments across 
disease sites. It is unclear how clinicians perceive their lung 
cancer patients compared with other patient groups.
If clinicians do indeed have more pessimistic views of 
lung cancer patients, could perception bias play a role? In other 
words, might these negative perceptions overgeneralize so that 
clinicians anticipate treatment difficulty, poor QOL, and higher 
symptom reports for individual lung cancer patients? The con-
cept of therapeutic nihilism has described this phenomenon and 
been used to explain variations in management of lung cancer 
patients.4,5 In addition to the impact on clinician perceptions 
of lung cancer patients, nihilistic attitudes may bias treatment 
decisions, limit patient access to evidence-based medicine, and 
reduce offers of clinical trials.6–10 Despite commentaries and 
indirect links with data, nihilistic attitudes in lung cancer have 
only been sparsely addressed in empirical research.11 To truly 
demonstrate the possibility of nihilism specific to lung cancer, 
Copyright © 2013 by the International Association for the Study of Lung 
Cancer
ISSN: 1556-0864/13/0812-1474
Clinician Perceptions of Care Difficulty, Quality of Life, and 
Symptom Reports for Lung Cancer Patients
An Analysis from the Symptom Outcomes and Practice  
Patterns (SOAPP) Study
Heidi A. Hamann, PhD,* Ju-Whei Lee, PhD,† Joan H. Schiller, MD,‡ Leora Horn, MD,§  
Lynne I. Wagner, PhD,||Victor Tsu-Shih Chang, MD,¶ and Michael J. Fisch, MD#
*Harold C. Simmons Cancer Center, Departments of Psychiatry and Clinical 
Sciences, University of Texas Southwestern Medical Center, Dallas, 
Texas; †Department of Biostatistics and Computational Biology, Dana 
Farber Cancer Institute, Boston, Massachusetts; ‡Harold C. Simmons 
Cancer Center, Department of Internal Medicine, University of Texas 
Southwestern Medical Center, Dallas, Texas; §Department of Medical 
Oncology, Vanderbilt University, Nashville, Tennessee; ‖Department of 
Medical Social Sciences, Northwestern University Feinberg School of 
Medicine, Chicago, Illinois; ¶VA New Jersey Health Care System, East 
Orange, New Jersey, Rutgers - New Jersey Medical School, Newark, New 
Jersey; and  #Department of General Oncology, The University of Texas 
MD Anderson Cancer Center, Houston, Texas.
Disclosure: The authors declare no conflict of interest. A portion of these data 
were presented at the American Society of Clinical Oncology (ASCO) 
annual meeting held in Chicago, Illinois on June 4-8, 2010.
Address for correspondence: Heidi A. Hamann, PhD, UT Southwestern 
Medical Center, 5323 Harry Hines Boulevard, Dallas, TX 75390. E-mail: 
Heidi.hamann@utsouthwestern.edu
<zdoi;10.1097/01.JTO.0000437501.83763.5d>
ORIGINAL ARTICLE
1475Copyright © 2013 by the International Association for the Study of Lung Cancer
Journal of Thoracic Oncology ®  •  Volume 8, Number 12, December 2013 Clinician Perceptions of Lung Cancer Patients
it is useful to compare across different cancers and show per-
ception and treatment disparities in the absence of clinical dif-
ferences. One approach involves vignette studies that present 
identically staged case scenarios to clinicians. For example, a 
study of referral decisions among primary care physicians com-
pared responses with identically staged case scenarios of breast 
and lung cancer.12 Results indicated that primary care physi-
cians were less likely to refer the advanced-stage lung cancer 
patient for further treatment and were also less likely to closely 
monitor her for uncontrolled pain. It was suggested that these 
findings may have been driven by physician nihilism and per-
ceptions of lung cancer as an untreatable disease.
Despite preliminary evidence of perception disparities 
from commentaries and vignette studies, we are unaware of 
assessments for potential bias and nihilism that include clini-
cians’ views of cancer patients under their care. Such assess-
ments within actual care settings are more difficult to interpret, 
based on the diversity of patient presentations within and across 
disease types. However, the ability to statistically control for 
explanatory variables, such as cancer stage, performance status 
(PS), and patient-reported QOL and symptom reports, allows 
greater understanding of potential perception differences and 
serves the foundation of the present analyses. Specifically, the 
goal of the current study was to assess clinician responses to 
their lung cancer patients compared with responses to their 
patients with breast, prostate, and colon cancer. In particular, we 
assessed clinicians’ perceptions of: (1) care difficulty, (2) QOL, 
and (3) symptom reports for patients under their care. We first 
examined overall patterns of disease-specific perceptions in 
order to assess whether lung cancer patients were judged dif-
ferently by their clinicians than patients with other solid tumors. 
We hypothesized that clinicians would report their lung cancer 
patients were more difficult to care for, had worse QOL, and had 
more symptom difficulties than patients with other solid tumors. 
To further investigate the possibility of nihilism and perception 
bias, we explored whether disease-specific differences persisted 
after the inclusion of other explanatory covariates (including 
stage, PS, and patient reports).
METHODS
Information about Eastern Cooperative 
Oncology Group Symptom Outcomes 
and Practice Patterns Study (E2Z02)
This report focuses on secondary analysis of data from 
the Eastern Cooperative Oncology Group (ECOG) Symptom 
Outcomes and Practice Patterns (SOAPP) study (E2Z02). In 
this study, patients with breast, colorectal, prostate, or lung 
cancer were enrolled from outpatient oncology clinics at any 
point in their care. The primary objective of the SOAPP study 
was to use cancer patient and clinician reports to describe the 
prevalence, severity, and interference of symptoms. This study 
was conducted in 38 institutions and enrolled 3123 patients 
between March 2006 and May 2008. Further study details can 
be found on the study Web site (www.ecogsoapp.com) and 
from the initial published article.13
Measures
Although many variables in the SOAPP study were 
measured twice (at initial and 4–5 week follow-up visits), pri-
mary data analysis only included assessments from the initial 
visit. All outcome measures were from forms completed at 
the initial assessment by each patient’s treating clinician (cli-
nician forms). Covariates were collected from both clinician 
and patient forms administered at the initial visit. Study aims 
focused on clinician-rated items that assessed (1) care diffi-
culty, (2) QOL, and (3) symptom reports (problems related to 
comorbidities, cancer, treatment, medication, weight change; 
Table 1). Post hoc analyses from the follow-up assessment 
were conducted only for variables that had significant effects 
in the multivariable analysis at the initial visit.
Statistical Analysis
Frequency and percentages were reported for each 
variable. Differences in patient and disease characteristics 
among groups were compared using χ2 tests. All outcome 
TABLE 1.  Clinician Ratings of Care Difficulty, Quality of Life, and Symptom Reports
Domain Item Scoring
Care difficulty Relative to other patients with same stage of disease, how would you categorize the degree of difficulty in 
caring for this patient’s physical/psychological symptoms?
1 = Very difficult
2 = Difficult
3 = Average
4 = Easier than average
5 = Much easier than average
Quality of life How would you rate this patient’s overall quality of life at this time? 1 = Very poor
2 = Poor
3 = Fair
4 = Good
5 = Excellent
Symptom reports Overall, how much do you think this patient is bothered by (a–e)?
a. difficulties related to comorbidities other than cancer
b. difficulties related directly to the cancer
c. difficulties related to treatment of cancer
d. side effects from medications used to treat pain or other symptoms
e. weight gain or loss
0 = Not at all
1 = A little bit
2 = Moderately
3 = Quite a bit
4 = Extremely
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TABLE 2.   Patient Demographics and Disease Characteristics by Disease Site at Initial Visit
Disease Site
Breast Colorectal Prostate Lung Total
N % N % N % N % N %
Number of patients 1544 50 718 23 320 10 524 17 3106 100
Age, yr
225 15 70 10 1 0 17 3 313 10  <45
  45 ≤ age < 60 652 42 247 34 45 14 140 27 1084 35
  60 ≤ age < 75 537 35 278 39 150 47 266 51 1231 40
  75 ≤ age 130 8 123 17 124 39 101 19 478 15
Sex
3 0 372 52 320 100 241 46 936 30  Male
  Female 1541 100 346 48 — — 283 54 2170 70
Race/ethnicity
305 21 201 30 81 28 95 20 682 24  Minority
  White and non-Hispanic 1127 79 475 70 210 72 381 80 2193 76
  Unknown 112 — 42 — 29 — 48 — 231 —
ECOG PS
1048 68 375 52 161 51 171 33 1755 57  0
  1 414 27 299 42 127 40 265 51 1105 36
  2–4 73 5 43 6 30 9 85 16 231 7
  Unknown 9 — 1 — 2 — 3 — 15 —
Weight loss, %
1369 90 565 79 286 91 411 79 2631 86  <5
  5–10 106 7 87 12 22 7 64 12 279 9
  ≥10 46 3 60 8 8 3 46 9 160 5
  Unknown 23 — 6 — 4 — 3 — 36 —
Current status of disease
806 53 243 34 45 14 63 12 1157 38  CR
  PR 45 3 28 4 26 8 48 9 147 5
  SD 525 34 324 45 174 55 313 60 1336 43
  PD 157 10 119 17 74 23 96 18 446 14
  Unknown 11 — 4 — 1 — 4 — 20 —
Current stage of disease
901 59 282 39 68 21 81 15 1332 43  NED
  Local/regional 241 16 95 13 77 24 176 34 589 19
  Metastatic 348 23 289 40 142 45 180 34 959 31
  Local/regional and metastatic 47 3 50 7 32 10 86 16 215 7
  Unknown 7 — 2 — 1 — 1 — 11 —
Metastatic sites
1106 72 345 48 144 45 239 46 1834 59  None
  Single site 211 14 202 28 129 40 143 27 685 22
  Multiple sites 227 15 171 24 47 15 142 27 587 19
Prior chemo/immuno/hormonal 
therapy
520 34 294 41 139 43 242 46 1195 38  No
  Yes 1024 66 424 59 181 57 281 54 1910 62
  Unknown 0 — 0 — 0 — 1 — 1 —
Prior radiation therapy
801 52 550 77 151 47 280 54 1782 58  No
  Yes 729 48 163 23 167 53 238 46 1297 42
  Unknown 14 — 5 — 2 — 6 — 27 —
(Continued )
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variables were assessed on a five-point ordinal scale. 
Univariate and multivariable cumulative logit models were 
fitted using generalized estimating equations to test the dis-
ease site effect for each outcome variable, with the worse 
ratings of each outcome variable being modeled. The main 
independent variable of disease site was fitted into the model 
with four levels, with a priori contrast on lung versus the 
other three (breast, colorectal, prostate) combined. If the dis-
ease site effect was significant, a post hoc comparison with 
family-wise error rate at 0.05 (using the Bonferroni correc-
tion, 0.05/6) was further conducted. For each outcome vari-
able, the covariates included age, sex, race/ethnicity, current 
status of disease, current stage of disease, metastatic sites, 
ECOG PS, weight loss in previous 6 months, currently receiv-
ing cancer treatment, prior chemotherapy/immunotherapy/
hormonal therapy, current radiation therapy, prior radiation 
therapy, institution type, clinic practice type, clinician type, 
and symptom burden (including the number of moderate/
severe symptoms, and the number of moderate/severe inter-
ference items as measured by the MD Anderson Symptom 
Inventory [MDASI]-ECOG). When available, patient reports 
of each outcome measure (e.g., QOL, symptom reports) were 
also model covariates. All covariates were treated as discrete 
variables (Tables 2 and 3).
For each outcome variable, only significant covariates 
(p < 0.10) in univariate models were further fitted into a mul-
tivariable model. Except for the covariate of race/ethnicity, 
patients with missing values on any of the variables in the 
analysis model were excluded from data analysis. All p val-
ues are two sided. A level of 5% was considered statistically 
significant except specified otherwise. SAS 9.2 (SAS Institute 
Inc., Cary, NC) was used for all data analyses.
Currently receiving cancer 
treatment
341 22 203 28 100 31 163 31 807 26  No
  Yes 1203 78 515 72 220 69 361 69 2299 74
Current radiation therapy
1448 95 686 96 296 93 460 88 2890 94  No
  Yes 75 5 27 4 22 7 60 12 184 6
  Unknown 21 — 5 — 2 — 4 — 32 —
Institution type
115 7 65 9 63 20 60 11 303 10  Academic
  Community 1429 93 653 91 257 80 464 89 2803 90
Clinic practice type
1188 77 500 70 219 68 417 80 2324 75  Majority-based
  Minority-based 356 23 218 30 101 32 107 20 782 25
Clinician
  Attending physician 1006 66 490 69 198 62 360 69 2054 67
  Resident or fellow 78 5 45 6 37 12 33 6 193 6
  Advanced practice nurse or 
nurse practitioner
158 10 58 8 13 4 36 7 265 9
  Physician assistant 59 4 17 2 13 4 27 5 116 4
  Other 222 15 101 14 59 18 64 12 446 14
  Unknown 21 — 7 — 0 — 4 — 32 —
Number of moderate/severe symptoms
  0 614 40 293 41 128 40 127 24 1162 38
  1–2 356 23 154 22 75 24 109 21 694 22
  3–6 331 22 134 19 77 24 147 28 689 22
  ≥7 237 15 131 18 38 12 140 27 546 18
  Unknown 6 — 6 — 2 — 1 — 15 —
Number of moderate/severe interference
  0 1009 66 444 63 195 61 246 47 1894 61
  1–2 221 14 119 17 56 18 97 19 493 16
  3–6 307 20 147 21 67 21 179 34 700 23
  Unknown 7 — 8 — 2 — 2 — 19 —
ECOG PS, Eastern Cooperative Oncology Group performance status; CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease; NED, no evidence of disease.
TABLE 2. (Continued )
Disease Site
Breast Colorectal Prostate Lung Total
N % N % N % N % N %
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RESULTS
Patient and Clinician Characteristics 
by Disease Site
Table 2 presents characteristics by disease site for all 
3106 analyzable patients: breast (50%), colorectal (23%), 
prostate (10%), and lung (17%). The median age of patients 
was 61 years (range, 18–93). The majority of patients were 
women (70%) with ECOG PS 0 (57%). Approximately one-
fourth (24%) were minority patients. In most cases (67%), 
clinician ratings were conducted by the patient’s attending 
physician; other clinician raters included residents, fellows, 
TABLE 3.  Frequency of Care Difficulty, QOL, and Symptom Ratings by Patients (by Disease Site)
Disease Site
TotalBreast Colorectal Prostate Lung
N % N % N % N % N %
Quality of life
  Excellent 400 26 136 19 56 18 48 9 640 21
  Good 802 52 335 47 149 47 244 47 1530 50
  Fair 280 18 198 28 93 29 172 33 743 24
  Poor 47 3 40 6 16 5 53 10 156 5
  Very poor 5 0 6 1 4 1 6 1 21 1
  Unknown 10 — 3 — 2 — 1 — 16 —
Comorbidity problem
  Not at all 533 35 293 41 99 31 158 30 1083 35
  A little bit 512 33 216 30 102 32 166 32 996 32
  Moderately 315 20 136 19 74 23 113 22 638 21
  Quite a bit 146 9 57 8 37 12 75 14 315 10
  Extremely 32 2 11 2 6 2 10 2 59 2
  Unknown 6 — 5 — 2 — 2 — 15 —
Disease problem
  Not at all 373 24 130 18 88 28 64 12 655 21
  A little bit 510 33 208 29 80 25 128 25 926 30
  Moderately 363 24 206 29 74 23 160 31 803 26
  Quite a bit 227 15 133 19 66 21 131 25 557 18
  Extremely 66 4 33 5 8 3 35 7 142 5
  Unknown 5 — 8 — 4 — 6 — 23 —
Disease treatment problem
  Not at all 416 27 142 20 115 36 79 15 752 24
  A little bit 441 29 193 27 86 27 147 28 867 28
  Moderately 379 25 196 28 58 18 156 30 789 26
  Quite a bit 219 14 148 21 48 15 109 21 524 17
  Extremely 80 5 29 4 9 3 26 5 144 5
  Unknown 9 — 10 — 4 — 7 — 30 —
Medication problem
  Not at all 622 41 298 42 164 52 184 35 1268 41
  A little bit 429 28 203 29 74 23 149 29 855 28
  Moderately 314 20 119 17 53 17 111 21 597 19
  Quite a bit 118 8 74 10 22 7 67 13 281 9
  Extremely 51 3 16 2 3 1 10 2 80 3
  Unknown 10 — 8 — 4 — 3 — 25 —
Weight problem
  Not at all 523 34 302 42 165 52 196 38 1186 38
  A little bit 433 28 206 29 78 25 142 27 859 28
  Moderately 298 19 110 15 45 14 84 16 537 17
  Quite a bit 202 13 69 10 23 7 79 15 373 12
  Extremely 81 5 27 4 6 2 21 4 135 4
  Unknown 7 — 4 — 3 — 2 — 16 —
QOL, quality of life.
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TABLE 4.  Frequency of Care Difficulty, QOL, and Symptom Ratings by Clinicians (by Disease Site)
Disease Site
Breast Colorectal Prostate Lung Total
N % N % N % N % N %
Care difficulty
  Very difficult 13 1 7 1 1 0 12 2 33 1
  Difficult 127 8 44 6 23 7 55 11 249 8
  Average 634 41 319 45 147 46 271 52 1371 44
  Easier than average 482 31 237 33 102 32 141 27 962 31
  Much easier than 
average
275 18 106 15 44 14 42 8 467 15
  Unknown 13 — 5 — 3 — 3 — 24 —
Quality of life
  Very poor 12 1 5 1 — — 7 1 24 1
  Poor 58 4 31 4 16 5 60 12 165 5
  Fair 395 26 234 33 102 32 230 44 961 31
  Good 760 50 337 47 155 49 196 38 1448 47
  Excellent 305 20 106 15 46 14 27 5 484 16
  Unknown 14 — 5 — 1 — 4 — 24 —
Comorbidity problem
  Not at all 701 46 337 47 108 34 162 31 1308 42
  A little bit 464 30 239 33 117 37 192 37 1012 33
  Moderately 242 16 90 13 61 19 105 20 498 16
  Quite a bit 111 7 41 6 30 9 51 10 233 8
  Extremely 12 1 8 1 3 1 11 2 34 1
  Unknown 14 — 3 — 1 — 3 — 21 —
Disease problem
  Not at all 615 40 236 33 85 27 97 19 1033 33
  A little bit 488 32 224 31 111 35 153 29 976 32
  Moderately 289 19 159 22 69 22 159 31 676 22
  Quite a bit 109 7 74 10 45 14 79 15 307 10
  Extremely 30 2 22 3 9 3 31 6 92 3
  Unknown 13 — 3 — 1 — 5 — 22 —
Disease treatment problem
  Not at all 468 31 138 19 94 30 96 18 796 26
  A little bit 544 36 245 34 130 41 185 36 1104 36
  Moderately 360 24 224 31 68 22 164 31 816 26
  Quite a bit 133 9 90 13 22 7 62 12 307 10
  Extremely 26 2 16 2 2 1 14 3 58 2
  Unknown 13 — 5 — 4 — 3 — 25 —
Medication problem
  Not at all 972 64 438 61 190 60 286 55 1886 61
  A little bit 394 26 175 25 91 29 159 31 819 27
  Moderately 111 7 69 10 30 9 56 11 266 9
  Quite a bit 40 3 27 4 7 2 13 3 87 3
  Extremely 11 1 4 1 1 0 5 1 21 1
  Unknown 16 — 5 — 1 — 5 — 27 —
Weight problem
  Not at all 1011 66 472 66 245 77 299 57 2027 66
  A little bit 328 21 160 22 46 14 134 26 668 22
  Moderately 116 8 56 8 18 6 52 10 242 8
  Quite a bit 63 4 22 3 7 2 33 6 125 4
  Extremely 1011 66 472 66 245 77 299 57 2027 66
  Unknown 15 — 3 — 1 — 3 — 22 —
QOL, quality of life.
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advanced practice nurses, and physician assistants. Significant 
differences were observed across disease sites on all variables 
listed in Table 2 (all p < 0.0001).
Table 3 includes patient-rated assessments of the cor-
responding dependent variables (except for care difficulty, 
which did not have a patient rating). The majority of patients 
(71%) reported “Good” or “Excellent” QOL. Most patients 
reported minimal (defined by “Not at all” or “A little bit”) dif-
ficulties related to comorbidities (67%), disease (51%), treat-
ment (52%), medications (69%), and weight (66%). Among 
the patient-reported outcomes listed in Table 3, significant dif-
ferences were observed among all of them across disease site 
overall and lung cancer versus others specifically (all p < 0.01). 
Lung cancer patients had significantly higher odds of reporting 
worse QOL (odds ratio [OR] = 8.4; 95% confidence interval 
[CI], 5.0–14.0; p < 0.0001) and more severe symptoms across 
all included domains (OR ranging from 2.2 to 6.6; all p < 0.01).
Clinician Perceptions of Patient Care 
Difficulty, QOL, and Symptom Reports
Table 4 lists frequency and percentage of clinician rat-
ings for various outcome variables at the initial visit. Table 5 
summarizes ORs and significance for both the disease site 
effect and the planned comparison between lung and other 
cancers for each outcome variable. Detailed descriptions for 
each item are described in the following sections.
Care Difficulty
The first study aim focused on clinician perceptions of 
care difficulty for lung cancer patients compared with breast, 
prostate, and colon cancer patients. Results from the univari-
ate logistic model indicated a significant disease site effect (p = 
0.0009) on the distribution of clinicians’ care difficulty ratings. 
In the planned comparison between lung and others, the odds 
of clinicians reporting more care difficulty ratings for patients 
with lung cancer were approximately five times higher than for 
those with other diseases (OR = 5.1; 95% CI, 2.5–10.4; p < 
0.0001). Conclusions from the univariate model did not hold 
after adjusting for other explanatory variables. The contrast 
(lung versus others) indicated that the odds of clinicians report-
ing more care difficulty ratings for patients with lung cancer 
were comparable with those with other diseases (OR = 1.5; 
95% CI, 0.8–2.9; p = 0.23), and there was no difference in the 
distribution of care difficulty ratings among the four disease 
sites after controlling for other explanatory variables (p = 0.60).
Quality of Life
The second study aim focused on comparing clinicians’ 
perceptions of patient QOL for lung versus other cancers. In 
addition to demographic and clinical variables, patient’s QOL 
rating at the initial visit was also a covariate in the multivari-
able model. A significant disease site effect (p < 0.0001) on 
the distribution of clinicians’ QOL ratings was found in the 
univariate logistic analysis. The prior comparison in QOL 
ratings indicated a significant difference (OR [lung ver-
sus others] = 17.9; 95% CI, 11.2–28.5; p < 0.0001). These 
conclusions remained even when the covariates were fitted 
into the multivariable model. The odds of clinicians report-
ing poorer QOL ratings for patients with lung cancer were 
about 3.6 times as large as for patients with other diseases 
(OR = 3.6; 95% CI, 2.0–6.6; p < 0.0001), supporting the expec-
tation that clinicians would report a worse QOL rating for lung 
cancer patients. Disease site effect was further evaluated by post 
hoc pairwise comparisons. As noted in the top half of Table 6, 
the odds of clinicians’ perceiving a poorer QOL for patients 
with breast and colorectal cancer were significantly lower than 
for patients with lung cancer. No statistically significant differ-
ence was observed between the other pairwise groups.
Post hoc analyses focused on clinician assessments of 
patient QOL at the follow-up visit. Results indicated that after 
adjusting for confounding factors, the odds of clinicians per-
ceiving lower QOL for their lung cancer patients were still 
3.2 times larger than for those with other solid tumors in the 
follow-up visit (OR = 3.2; 95% CI, 1.2–9.0; p = 0.04). The 
overall disease site effect was no longer significant in the mul-
tivariable model.
TABLE 5.  Odds Ratio and Significance of Disease (Dz) Site Effect and the Planned Comparison between Lung and Others for 
Various Outcome Items
Items
Univariable Model Multivariable Model
N
Dz Site Effect Lung vs. Others
N
Dz Site Effect Lung vs. Others
p p OR (95% CI) p p OR (95% CI)
Care difficultya 3082 0.0009 <0.0001 5.1 (2.5–10.4) 3010 0.60 0.23 1.5 (0.8–2.9)
QOLb 3082 <0.0001 <0.0001 17.9 (11.2–28.5) 3001 0.01 <0.0001 3.6 (2.0–6.6)
Comorbidityc 3085 0.0002 <0.0001 3.7 (2.1–6.6) 2971 0.07 0.09 1.6 (0.9–2.8)
Diseasec 3084 <0.0001 <0.0001 8.7 (4.6–16.3) 2978 0.17 0.10 1.7 (0.9–3.2)
Dz treatmentc 3081 0.0004 <0.0001 3.4 (1.9–5.9) 2962 0.008 0.89 1.0 (0.6–1.8)
Medicationc 3079 0.14 0.06 2.1 (1.0–4.6) 3017 0.82 0.56 0.8 (0.4–1.7)
Weightc 3084 0.003 <0.0001 5.1 (2.6–10.2) 2992 0.009 0.0004 3.2 (1.7–6.0)
aThe probabilities of having more care difficulty ratings were modeled in the analysis model.
b The probabilities of having worse QOL ratings were modeled in the analysis model.
cThe probabilities of having more bothersome ratings were modeled in the analysis model.
CI, confidence interval; QOL, quality of life; OR, odds ratio.
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Symptom Reports
The third study aim focused on comparing clinicians’ 
symptom reports for lung cancer patients with other patient 
groups. Several items related to this aim (symptom difficul-
ties related to comorbidity, disease, treatment, medication, 
weight) were analyzed separately to evaluate our hypotheses. 
For each of these clinician-reported items, patients’ symptom 
reports on the exact same item were included in the model as 
a covariate (in addition to covariates noted earlier).
Comorbidities. Results from the univariate logistic 
model showed a significant disease site effect (p = 0.0002) on 
the distribution of clinicians’ reports of patient comorbidity. 
The planned comparison in comorbidity reports also indicated 
significant difference, that is, the odds of clinicians reporting 
more bothersome comorbidity reports for lung cancer patients 
were approaching four times as high as for those with other 
disease (OR [lung versus others] = 3.7; 95% CI, 2.1–6.6; 
p < 0.0001). However, such a difference no longer existed in 
clinicians’ comorbidity reports among the four disease sites 
(p = 0.07) and between lung and others (p = 0.09) after adjust-
ing for other covariates (including patients’ responses on the 
same item) in the multivariable model.
Disease. Results from the univariate logistic model 
indicated a significant disease site effect (p < 0.0001) on cli-
nicians’ reports of disease difficulty, with a significant differ-
ence between lung and other cancers. Specifically, the odds 
of clinicians reporting more disease-related difficulties for 
lung cancer patients were almost nine times as high as for 
those with other cancers (OR [lung versus others] = 8.7; 95% 
CI, 4.6–16.3; p < 0.0001). This difference did not hold in cli-
nicians’ reports of disease difficulty among the four disease 
sites (p = 0.17) and between lung and others (p = 0.10) after 
controlling for other covariates (including patient’s response 
on the same item) in the multivariable model.
Disease Treatment. A significant disease site effect was 
observed for clinicians’ reports of difficulty related to disease 
treatment (p = 0.0004) using a univariate analysis. The planned 
comparison between lung and others found significant differ-
ence in ratings related to treatment difficulties (OR [lung ver-
sus others] = 3.4; 95% CI, 1.9–5.9; p < 0.0001). However, after 
adjusting for other covariates (including patients’ responses on 
the same item), no difference was found between clinicians’ 
reports of lung and others (p = 0.89). However, the overall 
disease site effect still reached significance (p = 0.008). As 
noted on the bottom half of Table 6, the odds of clinicians 
reporting more bothersome treatment difficulties for patients 
with colorectal cancer were significantly higher than for those 
with prostate and breast disease sites (both adjusted p < 0.05). 
No statistically significant difference in odds was observed 
between the other pairwise groups.
Side Effects from Medication. Disease site effect was 
not significant in the distribution of clinicians’ reports of med-
ication side effects, either in the univariate or the multivariable 
analysis models (p = 0.14 and p = 0.82, respectively). Nor was 
there any difference for clinician reports of medication side 
effects between lung cancer patients and patients with other 
disease (p = 0.06 in the univariate analysis and p = 0.56 in the 
multivariable analysis).
Weight Loss or Gain. A significant disease site effect on 
clinicians’ reports of bothersome weight loss or gain weight 
was observed (p = 0.003) in the univariate logistic regres-
sion analysis. Results from the planned comparison between 
lung and others found that the odds of clinicians reporting 
more weight-related difficulties for patients with lung can-
cer were about five times as large as for patients with other 
disease (OR [lung versus others] = 5.1; 95% CI, 2.6–10.2; 
p < 0.0001). After adjusting for other covariates (including 
patient’s response on the same item), the same difference 
pattern was found between clinicians’ reports between lung 
TABLE 6.  Odds Ratio of Having Worse Ratings on QOL and Disease (Dz) Treatment in Each Disease Site with Respect to Each 
Other Site (Row to Column)
Item Breast Colorectal Prostate Lung
QOL Breast 1 1.1 1.1 0.7a
(0.8–1.4) (0.7–1.6) (0.5–0.9)
Colorectal 1 1.0 0.6a
(0.8–1.5) (0.5–0.8)
Prostate 1 0.6
(0.4–0.9)
Lung 1
Dz treatment Breast 1 0.7a 1.1 0.9
(0.5–0.9) (0.7–1.7) (0.7–1.1)
Colorectal 1 1.7a 1.4
(1.2–1.4) (1.1–1.7)
Prostate 1 0.8
(0.6–1.1)
Lung 1
Numbers in parentheses are 95% confidence limits of odds ratio.
aAdjusted p < 0.05.
QOL, quality of life.
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and others (OR [lung versus others] = 3.2; 95% CI, 1.7–6.0; 
p = 0.0004). The disease site effect also remained significant 
(p = 0.009), primarily because the odds of having more both-
ersome clinician weight ratings for patients with lung cancer 
were significantly higher than for those with prostate cancer 
(OR = 1.7; 95% CI, 1.4–2.5; adjusted p < 0.05). No statisti-
cally significant difference in odds was observed between the 
other pairwise groups. No parallel analysis for the follow-up 
assessment could be performed because the weight question 
was not included in the follow-up clinician form.
CONCLUSION
This study represents a novel attempt to compare clini-
cian perceptions of care difficulty, QOL, and symptom reports 
for patients with lung cancer with those of patients with other 
solid tumors. Analyses focused on both univariate compari-
sons and multivariable comparisons that controlled for a com-
prehensive array of patient, disease, and setting variables.
Overall, clinicians had more pessimistic attitudes about 
their lung cancer patients. In the univariate comparisons, cli-
nicians rated their lung cancer patients as more difficult to 
treat, with poorer QOL, and higher symptom reports (inclu-
sive of difficulties related to cancer, comorbidities, treatment, 
and weight change). Despite the general findings, analyses 
intended to isolate potential perception bias and nihilism dem-
onstrated mixed findings. For most of the outcome variables, 
the inclusion of patient reports, clinical factors (e.g., cancer 
stage, PS), and other explanatory covariates negated differ-
ences in clinician perceptions of lung cancer versus other 
patient groups. However, clinicians continued to perceive 
their lung cancer patients as having a poorer QOL (at both 
baseline and follow-up assessments) and more difficulties 
related to weight, even after controlling for these explanatory 
factors (including patient reports of the outcome variables).
The findings of this study suggest that certain clinician 
judgments (i.e., QOL and weight problems) may have been 
influenced by preexisting ideas (e.g., nihilism) about lung can-
cer patients and their treatment options. In essence, even if 
their lung cancer patients were sicker than their other solid 
tumor patients, clinicians perceived their QOL to be lower 
and weight difficulties as more burdensome after controlling 
for how sick they were. In the case of QOL, these percep-
tions were consistent over time; both baseline and follow-up 
assessments revealed this difference. Lung cancer patients have 
complicated symptom burdens and are difficult to treat; our 
data show that clinicians are well aware of these complexities. 
However, the data also suggest that this complexity perhaps 
provides a smokescreen to hide a subtle, but potentially real, 
underlying bias and nihilism.
Associations between smoking and lung cancer may 
affect clinicians’ views, both through possible perceptions 
of blame and anticipated treatment nonadherence associ-
ated with behavioral risk factors.11,12 Given that a subset of 
findings suggests that features of nihilism do persist, further 
exploration of this issue is needed. Fortunately, the current 
landscape surrounding lung cancer care looks very different 
than it did as little as a decade ago. Recent evidence from the 
National Lung Screening Trial suggests promise in computed 
tomography–based screening for early detection and reduced 
mortality associated with lung cancer.14 Molecular character-
ization of lung cancer (such as testing tumors for epidermal 
growth factor receptor [EGFR] and anaplastic lymphoma 
kinase [ALK] rearrangements) has enabled oncologists 
to identify subsets of patients who respond to specific and 
effective treatments other than (or in addition to) standard 
chemotherapy.15–20 There are not only new therapeutics and 
extended expected survival times, but also more favor-
able toxicity profiles for many of the new treatments. Such 
advances have led to suggestions of the “end of the era of 
therapeutic nihilism” as it relates to lung cancer.7 This may 
very well be the case; as lung cancer becomes more treatable, 
perceptions of lung cancer patients and their difficulty of care 
may also improve. Data from this study indicate that research 
is needed to fully understand the breadth and depth of nihil-
ism and consequences to treatment decisions and clinician–
patient communication (including the potential relationship 
between clinician nihilism and patient perceptions of lung 
cancer stigma).21 Although certain studies suggest a tendency 
to undertreat lung cancer patients specifically (i.e., not adhere 
to evidence-based guidelines for first- and second-line thera-
pies)12,22,23 other data describe potential overtreatment, espe-
cially for advanced cancer patients.24,25 Low accrual to lung 
cancer clinical trials is a clear concern,26 and emerging evi-
dence identifies provider factors associated with clinical trial 
involvement and referrals.27,28 However, the extent to which 
provider nihilism may affect how clinical trials are offered to 
lung cancer patients is unclear and needs further investiga-
tion. Any potential relationship between nihilism and treat-
ment decisions, including decisions to offer clinical trials to 
patients, is likely to be complex. As more information is gath-
ered about clinician views of lung cancer patients and their 
treatment outcomes, it is important to consider educational 
interventions for all health professionals who influence the 
patient experience of dealing with lung cancer.
Overall, it is very difficult to prove that perception bias 
and nihilism are the only factors or main factors contributing 
to our study findings related to clinician perceptions of QOL 
and weight difficulties. Even with comprehensive covariates, 
there may be unmeasured factors that are disproportionately 
present in lung cancer patients and contribute to demonstrated 
differences in clinician perceptions. Perhaps clinicians are not 
nihilistic about QOL and weight concerns in patients with 
lung cancer, but are instead able to incorporate factors elusive 
to the usual summaries of patients, disease, and treatment. 
However, by suggesting a subtle, potentially real, underlying 
bias and nihilism, these findings are provocative and should be 
further investigated for confirmation and exploration of their 
underpinnings.
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